Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1985 1
1986 1
1987 2
1988 5
1989 10
1990 12
1991 11
1992 12
1993 17
1994 12
1995 19
1996 17
1997 16
1998 10
1999 14
2000 8
2001 15
2002 15
2003 11
2004 10
2005 11
2006 8
2007 5
2008 6
2009 6
2010 7
2011 7
2012 5
2013 5
2014 1
2015 5
2016 2
2017 2
2018 2
2019 1
2020 5
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses.
Honkalammi J, Niemi M, Neuvonen PJ, Backman JT. Honkalammi J, et al. Clin Pharmacol Ther. 2012 May;91(5):846-55. doi: 10.1038/clpt.2011.313. Clin Pharmacol Ther. 2012. PMID: 22472994 Clinical Trial.
Therapeutic doses of gemfibrozil cause mechanism-based inactivation of CYP2C8 via formation of gemfibrozil 1-O-beta-glucuronide. ...On the basis of a mechanism-based inactivation model involving gemfibrozil 1-O-beta-glucuronide, a gemfibrozil dose of 3 …
Therapeutic doses of gemfibrozil cause mechanism-based inactivation of CYP2C8 via formation of gemfibrozil 1-O-beta-glucuronid …
Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.
Garg A, Grundy SM. Garg A, et al. Diabetes. 1989 Mar;38(3):364-72. doi: 10.2337/diab.38.3.364. Diabetes. 1989. PMID: 2917701 Clinical Trial.
To examine the potential of hypolipidemic drugs for therapy of lipoprotein abnormalities in NIDDM, 10 patients maintaining marked (plasma triglycerides greater than 500 mg/dl) and 6 with moderate (plasma triglycerides 250-500 mg/dl) hypertriglyceridemia, despite good glycemic con …
To examine the potential of hypolipidemic drugs for therapy of lipoprotein abnormalities in NIDDM, 10 patients maintaining marked (plasma tr …
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Backman JT, et al. Clin Pharmacol Ther. 2002 Dec;72(6):685-91. doi: 10.1067/mcp.2002.128469. Clin Pharmacol Ther. 2002. PMID: 12496749 Clinical Trial.
Our aim was to study the effect of gemfibrozil on cerivastatin pharmacokinetics. METHODS: In a randomized, double-blind crossover study, 10 healthy volunteers took 600 mg gemfibrozil or placebo twice daily for 3 days. ...CONCLUSIONS: Gemfibrozil greatly incre …
Our aim was to study the effect of gemfibrozil on cerivastatin pharmacokinetics. METHODS: In a randomized, double-blind crossover stu …
Effect of gemfibrozil on the pharmacokinetics of pioglitazone.
Deng LJ, Wang F, Li HD. Deng LJ, et al. Eur J Clin Pharmacol. 2005 Dec;61(11):831-6. doi: 10.1007/s00228-005-0042-6. Epub 2005 Nov 8. Eur J Clin Pharmacol. 2005. PMID: 16283275 Clinical Trial.
No statistically significant changes were seen in the total AUC of M-III or M-IV after gemfibrozil pretreatment. Gemfibrozil reduced the M-III/pioglitazone and M-IV/pioglitazone AUC(0-infinity) ratio by 71% (P<0.001) and 65%(P<0.001), strikingly prolonging the …
No statistically significant changes were seen in the total AUC of M-III or M-IV after gemfibrozil pretreatment. Gemfibrozil r …
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ. Jaakkola T, et al. Clin Pharmacol Ther. 2005 May;77(5):404-14. doi: 10.1016/j.clpt.2004.12.266. Clin Pharmacol Ther. 2005. PMID: 15900286 Clinical Trial.
METHODS: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itraconazole (first dose, 200 mg), both gemfibrozil and itraconazole, or placebo twice daily for 4 days. ...However, studies in diabetic p …
METHODS: In a randomized, double-blind, 4-phase crossover study, 12 healthy volunteers took either 600 mg gemfibrozil or 100 mg itrac …
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Niemi M, et al. Diabetologia. 2003 Oct;46(10):1319-23. doi: 10.1007/s00125-003-1181-x. Epub 2003 Jul 29. Diabetologia. 2003. PMID: 12898007 Clinical Trial.
AIMS/HYPOTHESIS: Our aim was to investigate possible interaction between gemfibrozil and rosiglitazone, a thiazolidinedione antidiabetic drug. ...The peak plasma rosiglitazone concentration (C(max)) was increased only 1.2-fold (range 0.9- to 1.6-fold; p=0.01) by gemfibr …
AIMS/HYPOTHESIS: Our aim was to investigate possible interaction between gemfibrozil and rosiglitazone, a thiazolidinedione antidiabe …
Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, Hartman D. Whitfield LR, et al. J Clin Pharmacol. 2011 Mar;51(3):378-88. doi: 10.1177/0091270010366446. Epub 2010 Apr 22. J Clin Pharmacol. 2011. PMID: 20413454 Clinical Trial.
This study compared the effects of multiple-dose administration of gemfibrozil and fenofibrate on the single-dose pharmacokinetics of atorvastatin. Gemfibrozil coadministration led to significant increases in the AUC of atorvastatin, 2-hydroxyatorvastatin, 2-hydroxy …
This study compared the effects of multiple-dose administration of gemfibrozil and fenofibrate on the single-dose pharmacokinetics of …
The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. Schneck DW, et al. Clin Pharmacol Ther. 2004 May;75(5):455-63. doi: 10.1016/j.clpt.2003.12.014. Clin Pharmacol Ther. 2004. PMID: 15116058 Clinical Trial.
Therefore the effect of gemfibrozil on rosuvastatin pharmacokinetics was assessed in healthy volunteers. ...Care is warranted when gemfibrozil is coadministered with rosuvastatin and other statins....
Therefore the effect of gemfibrozil on rosuvastatin pharmacokinetics was assessed in healthy volunteers. ...Care is warranted when …
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride.
Niemi M, Neuvonen PJ, Kivistö KT. Niemi M, et al. Clin Pharmacol Ther. 2001 Nov;70(5):439-45. doi: 10.1067/mcp.2001.119723. Clin Pharmacol Ther. 2001. PMID: 11719730 Clinical Trial.
METHODS: In a randomized, 2-phase crossover study, 10 healthy volunteers were treated for 2 days with 600 mg oral gemfibrozil or placebo twice daily. On day 3, they received a single dose of 600 mg gemfibrozil or placebo and 1 hour later a single dose of 0.5 mg glim …
METHODS: In a randomized, 2-phase crossover study, 10 healthy volunteers were treated for 2 days with 600 mg oral gemfibrozil or plac …
Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects.
Nicolas JM, Chanteux H, Rosa M, Watanabe S, Stockis A. Nicolas JM, et al. Drug Metab Dispos. 2012 Aug;40(8):1466-72. doi: 10.1124/dmd.112.045328. Epub 2012 Apr 26. Drug Metab Dispos. 2012. PMID: 22538270 Clinical Trial.
Gemfibrozil-1-O-beta-glucuronide had no relevant effect on either reaction (K(I) >200 muM). In conclusion, gemfibrozil did not influence the pharmacokinetics of BRV and its hydroxylation into BRV-OH. ...
Gemfibrozil-1-O-beta-glucuronide had no relevant effect on either reaction (K(I) >200 muM). In conclusion, gemfibrozil did …
287 results

Searches related to "gemfibrozil"